Literature DB >> 28421555

Pharmacological Agents Affecting Emesis : A Review (Part II).

F Mitchelson1.   

Abstract

Part I of this article reviewed the pathophysiology of emesis, and its pharmacological treatment. Drug-induced vomiting was also discussed. In the second part of the review, other common causes of vomiting are considered.The basis of the use of antiemetics in morning sickness and migraine is still obscure; for the latter, serotonin 5-HT1 receptor agonists, 5-HT3 receptor antagonists and dopamine D2 receptor antagonists are effective. For motion sickness, control can be achieved with various antagonists of muscarinic or histamine H1-receptors. Centrally active adrenoceptor agonists in combination with a muscarinic antagonist or H1-receptor antagonist may offer better control of motion sickness and its associated symptoms than either antagonist alone; based on clinical studies, post-operative vomiting after opiate administration appears to be controlled by blocking dopamine D2, histamine H1-or muscarinic receptors.Radiation therapy appears to be similar to cytotoxic therapy in that the mediators produced or released by radiation activate both peripheral and central sites involved in the vomiting reflex. Blockade of dopamine D2 and 5-HT3 receptors may be effective.

Entities:  

Year:  1992        PMID: 28421555     DOI: 10.2165/00003495-199243040-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  377 in total

Review 1.  Minor complications of general anaesthesia.

Authors:  J E Riding
Journal:  Br J Anaesth       Date:  1975-02       Impact factor: 9.166

Review 2.  FACTORS THAT INFLUENCE POSTOPERATIVE VOMITING.

Authors:  I E PURKIS
Journal:  Can Anaesth Soc J       Date:  1964-07

3.  Tacrine in Alzheimer's disease.

Authors:  B Davies; D Andrewes; R Stargatt; D Ames; V Tuckwell; S Davis
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

4.  The influence of thiethylperazine on the absorption of effervescent aspirin in migraine.

Authors:  G Wainscott; T Kaspi; G N Volans
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

5.  Spectral analysis of tachygastria recorded during motion sickness.

Authors:  R M Stern; K L Koch; W R Stewart; I M Lindblad
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

6.  Effects of eliminating nitrous oxide in outpatient anesthesia.

Authors:  B M Melnick; L S Johnson
Journal:  Anesthesiology       Date:  1987-12       Impact factor: 7.892

7.  Stimulant effects of enkephalin microinjection into the dopaminergic A10 area.

Authors:  C L Broekkamp; A G Phillips; A R Cools
Journal:  Nature       Date:  1979-04-05       Impact factor: 49.962

8.  The pharmacologic absis for the control of motion sickness by drugs.

Authors:  J Brand
Journal:  Pharmacol Physicians       Date:  1968-03

9.  Astemizole. Its use in the treatment of patients with chronic vertigo.

Authors:  R T Jackson; J S Turner
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-05

10.  Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.

Authors:  S Frytak; C G Moertel; J R O'Fallon; J Rubin; E T Creagan; M J O'Connell; A J Schutt; N W Schwartau
Journal:  Ann Intern Med       Date:  1979-12       Impact factor: 25.391

View more
  2 in total

Review 1.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 2.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.